HTHSCI 1DT3 Lecture Notes - Lecture 5: Smoking Cessation, Neutrophil, Elastin
13 Aug 2020
School
Department
Course
Professor
Document Summary
Mod. 1-20 new pharmacotherapy for copd 1. Introduction: the need for new therapies, major health problem and is increasing through the world, especially in developing countries. High health care and welfare costs: highly associated with smoking, but it is difficult to stop smoking. Potassium channels openers are effective in vitro, but not in vivo as they were more potent as vasodilators and limited the dosage used. Interest to develop rho kinase inhibitors & smooth muscle myosin inhibitors, but due to vasodilation side effects. It would be necessary to administer them by inhalation: laba indacaterol (once a day b-agonist) vs. salmeterol (twice a day) Indacaterol vs. salmeterol vs. placebo 170ml vs. 60ml vs. 0ml (normalised to placebo) Boehringer: olodaterol + tiotropium: twice daily cipla: formoterol + tiotropium. Pearl: formoterol + glycopyrrolate: triohale (triple combi): formoterol + tiotropium + budesonide, but copd patients do not require steroids, while asthmatics do not require anti-cholinergics. Mod. 1-20 new pharmacotherapy for copd 2.
